Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... vs <4 red blood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); ...

    Research Article last updated 09/18/2017 - 1:38pm.

  2. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

    ... ⩽10 g/dl, low transfusion burden, and serum erythropoietin ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ... of 9.3 (Q1:8.8, Q3:9.7) g/dl and median baseline serum erythropoietin of 69 (Q1:36, Q3:158) mU/ml. Transfusion incidence from weeks ...

    Research Article last updated 07/11/2017 - 10:16am.

  3. Top honor goes to AAMDSIF Medical Advisor

    ... which time he studied oxygen-regulated expression of the erythropoietin gene at Oxford with Peter Ratcliffe. He received his MD from ...

    Article last updated 08/29/2017 - 7:54am.

  4. Treatment of low-risk myelodysplastic syndromes

    ... is performed on the basis of IPSS-R, endogenous erythropoietin levels, and transfusion independence . Doses and ...

    Research Article last updated 01/26/2017 - 10:42am.

  5. MDS Follows Two Misdiagnoses

    ... as relatively low risk. I have been treated with erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.

  6. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis

    ... response duration range was 12-51+ months. Patients with erythropoietin (EPO) <100 iu/l had 35% [95% confidence interval (CI): ...

    Research Article last updated 06/23/2016 - 9:14am.

  7. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, ...

    Research Article last updated 07/18/2016 - 10:30am.

  8. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes

    ... National Comprehensive Cancer Network guidelines: serum erythropoietin determination before ESA initiation, ... the observation period, with increased rates of serum erythropoietin levels, but declined in the other two guidelines. ...

    Research Article last updated 01/20/2015 - 1:05pm.

  9. Eltrombopag in aplastic anemia

    ... granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) have not improved outcome. A recent trial has shown ...

    Research Article last updated 03/02/2015 - 12:51pm.

  10. Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative

    ... and classification of MDS and in the documentation of erythropoietin levels. Improvements related to patient communication and ...

    Research Article last updated 02/08/2013 - 7:53am.